- Home
- KLRS vs PAVS Comparison
KLRS vs PAVS Comparison
Compare KLRS & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- PAVS
- Stock Information
- Founded
- KLRS 2019
- PAVS 2004
- Country
- KLRS United States
- PAVS United States
- Employees
- KLRS N/A
- PAVS N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- KLRS Health Care
- PAVS Health Care
- Exchange
- KLRS Nasdaq
- PAVS Nasdaq
- Market Cap
- KLRS 46.0M
- PAVS 45.1M
- IPO Year
- KLRS N/A
- PAVS 2019
- Fundamental
- Price
- KLRS $6.31
- PAVS $1.05
- Analyst Decision
- KLRS Strong Buy
- PAVS
- Analyst Count
- KLRS 3
- PAVS 0
- Target Price
- KLRS $21.50
- PAVS N/A
- AVG Volume (30 Days)
- KLRS 147.9K
- PAVS 717.1K
- Earning Date
- KLRS 11-12-2025
- PAVS 08-04-2025
- Dividend Yield
- KLRS N/A
- PAVS N/A
- EPS Growth
- KLRS N/A
- PAVS N/A
- EPS
- KLRS N/A
- PAVS N/A
- Revenue
- KLRS N/A
- PAVS $71,542.00
- Revenue This Year
- KLRS N/A
- PAVS N/A
- Revenue Next Year
- KLRS N/A
- PAVS N/A
- P/E Ratio
- KLRS N/A
- PAVS N/A
- Revenue Growth
- KLRS N/A
- PAVS N/A
- 52 Week Low
- KLRS $2.14
- PAVS $0.43
- 52 Week High
- KLRS $12.90
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- KLRS 57.79
- PAVS 75.38
- Support Level
- KLRS $6.04
- PAVS $0.56
- Resistance Level
- KLRS $7.07
- PAVS $0.74
- Average True Range (ATR)
- KLRS 0.66
- PAVS 0.13
- MACD
- KLRS 0.08
- PAVS 0.05
- Stochastic Oscillator
- KLRS 64.94
- PAVS 81.82
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.